
    
      Research design: randomized, double-blind, placebo-controlled crossover study Patients:
      Microalbuminuric (urinary albumin excretion [UAE]30-300 mg/d)type 2 diabetes mellitus
      patients without ischemic heart disease or peptic ulcer Aim:To evaluate the putative
      interference of low-dose aspirin (300 mg/d)for 8 weeks)on enalapril antiproteinuric
      properties in microalbuminuric type 2 diabetes mellitus patients Study protocol:Crossover
      randomization to 8 weeks of enalapril 10 mg/d plus aspirin (300 mg/d) or plus placebo, and a
      6-week washout period. Measurement of UAE (immunoturbidimetry) and glomerular filtration rate
      (51Cr-EDTA), blood pressure and metabolic control at baseline and at the end of each period.

      Statistical analyses: Bland&Altman analyses for crossover trials.
    
  